Search results
Showing 61 to 75 of 158 results for urinary tract infections
Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.
View recommendations for IPG697Show all sections
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
Question Indwelling urinary catheters: catheter selection:- For patients using a long-term indwelling urinary catheter,...
Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids (IPG30)
Evidence-based recommendations on magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids. This involves passing laser heat through needles inserted into the fibroid to destroy it.
View recommendations for IPG30Show all sections
Sections for IPG30
Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.
View recommendations for IPG766Show all sections
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
They include: : Infections, including vaginal infections and urinary tract infections. : Wound complications,...
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)
Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)
Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gastro-oesophageal reflux in children and young people (QS112)
This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.
View quality statements for QS112Show all sections
Sections for QS112
- Quality statements
- Quality statement 1: Information about gastro-oesophageal reflux (GOR) in infants
- Quality statement 2: Breast-fed infants – feeding assessment
- Quality statement 3: Formula-fed infants – stepped-care approach
- Quality statement 4: Alginate therapy
- Quality statement 5: Symptoms that do not need investigation or treatment
- Quality statement 6: Acid-suppressing drugs
- Quality statement 7: Upper gastrointestinal (GI) contrast study
of urinary tract infection in children and young people aged 5 years and above but under 16 years: What are...
Electrocautery cutting balloon treatment for pelviureteric junction obstruction (IPG324)
Evidence-based recommendations on electrocautery cutting balloon treatment for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting a catheter with a balloon and wire into the urinary tract.
View recommendations for IPG324Show all sections
Sections for IPG324